Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Infect Control Hosp Epidemiol ; 35(3): 265-71, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24521592

ABSTRACT

BACKGROUND AND OBJECTIVE: Antimicrobial stewardship programs (ASPs) are a mechanism to ensure the appropriate use of antimicrobials. The extent to which ASPs are formally implemented in freestanding children's hospitals is unknown. The objective of this study was to determine the prevalence and characteristics of ASPs in freestanding children's hospitals. METHODS: We conducted an electronic survey of 42 freestanding children's hospitals that are members of the Children's Hospital Association to determine the presence and characteristics of their ASPs. For hospitals without an ASP, we determined whether stewardship strategies were in place and whether there were barriers to implementing a formal ASP. RESULTS: We received responses from 38 (91%) of 42. Among responding institutions, 16 (38%) had a formal ASP, and 15 (36%) were in the process of implementing a program. Most ASPs (13 [81%] of 16) were started after 2007. The median number of full-time equivalents dedicated to ASPs was 0.63 (range, 0.1-1.8). The most common antimicrobials monitored by ASPs were linezolid, vancomycin, and carbapenems. Many hospitals without a formal ASP were performing stewardship activities, including elements of prospective audit and feedback (9 [41%] of 22), formulary restriction (9 [41%] of 22), and use of clinical guidelines (17 [77%] of 22). Antimicrobial outcomes were more likely to be monitored by hospitals with ASPs (100% vs 68%; P = .01), although only 1 program provided support for a data analyst. CONCLUSIONS: Most freestanding children's hospitals have implemented or are developing an ASP. These programs differ in structure and function, and more data are needed to identify program characteristics that have the greatest impact.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Utilization Review/statistics & numerical data , Hospitals, Pediatric/statistics & numerical data , Child , Data Collection , Drug Utilization Review/methods , Drug Utilization Review/organization & administration , Feedback , Hospitals, Pediatric/organization & administration , Humans , Prevalence , United States/epidemiology
2.
Pediatr Infect Dis J ; 33(1): e14-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24352192

ABSTRACT

We used the Pediatric Health Information System to evaluate linezolid use among hospitalized children. From 2003 to 2007, use increased 5-fold, including wide interhospital variation, then stabilized through 2011. Linezolid was responsible for 3% of total antibiotic expenditures. Children with respiratory, oncologic or transplant conditions were the most frequently treated with linezolid.


Subject(s)
Acetamides/administration & dosage , Anti-Bacterial Agents/administration & dosage , Drug Prescriptions/statistics & numerical data , Hospitalization/statistics & numerical data , Oxazolidinones/administration & dosage , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Linezolid , Male , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections/drug therapy
3.
J Pediatric Infect Dis Soc ; 2(4): 379-81, 2013 Dec.
Article in English | MEDLINE | ID: mdl-26619500

ABSTRACT

Children presenting to an emergency department following an animal bite were found to be at risk for infection if they had puncture wounds, crush wounds, or were bitten by a cat. Of the infected wounds that were cultured, methicillin-resistant Staphylococcus aureus was not isolated as a pathogen.

4.
Pediatrics ; 129(3): e597-604, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22351891

ABSTRACT

OBJECTIVES: We sought to describe the impact a clinical practice guideline (CPG) had on antibiotic management of children hospitalized with community-acquired pneumonia (CAP). PATIENTS AND METHODS: We conducted a retrospective study of discharged patients from a children's hospital with an ICD-9-CM code for pneumonia (480-486). Eligible patients were admitted from July 8, 2007, through July 9, 2009, 12 months before and after the CAP CPG was introduced. Three-stage least squares regression analyses were performed to examine hypothesized simultaneous relationships, including the impact of our institution\x{2019}s antimicrobial stewardship program (ASP). RESULTS: The final analysis included 1033 patients: 530 (51%) before the CPG (pre-CPG) and 503 (49%) after the CPG (post-CPG). Pre-CPG, ceftriaxone (72%) was the most commonly prescribed antibiotic, followed by ampicillin (13%). Post-CPG, the most common antibiotic was ampicillin (63%). The effect of the CPG was associated with a 34% increase in ampicillin use (P < .001). Discharge antibiotics also changed post-CPG, showing a significant increase in amoxicillin use (P < .001) and a significant decrease in cefdinir and amoxicillin/clavulanate (P < .001), with the combined effect of the CPG and ASP leading to 12% (P < 0.001) and 16% (P < .001) reduction, respectively. Overall, treatment failure was infrequent (1.5% vs 1%). CONCLUSIONS: A CPG and ASP led to the increase in use of ampicillin for children hospitalized with CAP. In addition, less broad-spectrum discharge antibiotics were used. Patient adverse outcomes were low, indicating that ampicillin is appropriate first-line therapy for otherwise healthy children admitted with uncomplicated CAP.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Community-Acquired Infections/drug therapy , Pneumonia, Bacterial/drug therapy , Practice Guidelines as Topic/standards , Age Distribution , Child , Child, Preschool , Cohort Studies , Community-Acquired Infections/diagnosis , Community-Acquired Infections/epidemiology , Female , Follow-Up Studies , Hospitalization/statistics & numerical data , Humans , Incidence , Infant , International Classification of Diseases , Male , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/epidemiology , Radiography, Thoracic , Reference Values , Retrospective Studies , Risk Assessment , Sex Distribution , Treatment Outcome
5.
Pediatr Infect Dis J ; 31(1): 37-41, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21892124

ABSTRACT

BACKGROUND: Infection with Escherichia coli O157 (O157) can lead to the development of hemolytic uremic syndrome (HUS). Treating O157 infections with antibiotics is a possible risk factor for HUS development; however, previous studies evaluating this relationship have yielded conflicting results. The objective of this study was to further evaluate this issue. METHODS: An age-matched case-case comparison study comprising Minnesota residents less than 20 years of age with culture-confirmed O157 infection who did (n = 66) or did not (n = 129) subsequently develop HUS was conducted. Subjects were identified through statewide surveillance activities by the Minnesota Department of Health from 1996 to 2002. RESULTS: Overall antibiotic treatment was not associated with the development of HUS. Self-reported vomiting and female gender were significantly associated with the development of HUS. After adjustment for illness severity and gender, subjects who developed HUS were more likely to have been treated only with bactericidal antibiotics within the first 3 days (adjusted matched odds ratio [OR], 12.4; 95% confidence interval [CI], 1.4-110.3) or within the first 7 days (OR, 18.0; 95% CI, 1.9-170.9) after the onset of diarrhea. In particular, the use of ß-lactams (penicillins or cephalosporins) in the first 3 days after diarrhea onset was also significant after adjustment (OR, 11.3; 95% CI, 1.2-106.7). CONCLUSIONS: Individuals infected with O157 infection presenting with a more severe illness were at an increased risk of developing HUS. The use of bactericidal antibiotics, particularly ß-lactams, to treat O157 infection was associated with the subsequent development of HUS.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Escherichia coli Infections/drug therapy , Escherichia coli O157/drug effects , Hemolytic-Uremic Syndrome/etiology , Adolescent , Anti-Bacterial Agents/adverse effects , Case-Control Studies , Child , Child, Preschool , Escherichia coli Infections/complications , Escherichia coli Infections/microbiology , Escherichia coli Infections/physiopathology , Female , Hemolytic-Uremic Syndrome/epidemiology , Hemolytic-Uremic Syndrome/microbiology , Humans , Infant , Infant, Newborn , Male , Minnesota/epidemiology , Risk Factors , Severity of Illness Index , Young Adult , beta-Lactams/adverse effects , beta-Lactams/therapeutic use
6.
J Pediatric Infect Dis Soc ; 1(3): 190-7, 2012 Sep.
Article in English | MEDLINE | ID: mdl-26619407

ABSTRACT

BACKGROUND: In pediatrics, limited data are available on how to develop and implement an antimicrobial stewardship program (ASP). In addition, no data exist on clinicians' impression of such programs. The objectives of this study were to describe the development and implementation of an ASP in a children's hospital and to describe the thoughts and attitudes of the clinicians interacting with the ASP. METHODS: A qualitative description of the development and implementation of an ASP is provided. In addition, 2 years after the implementation of a prospective-audit-with-feedback ASP, an electronic survey was administered to clinicians to assess their attitudes toward the ASP. RESULTS: A 5-step process for developing this ASP included the following: team development; selecting the stewardship strategy(ies) and antimicrobials to monitor; establishing a method to identify patients; program evaluation; and implementation. Of 365 participants surveyed, 205 (56%) responded, and 80% (160 of 199) had never worked with an ASP before its implementation. Clinicians agreed that the ASP decreased inappropriate use of antibiotics (84%, 162 of 194), improved the quality of patient care (82%, 159 of 194), and provided knowledge and education about appropriate antibiotic use (91%, 177 of 194). Negative feelings regarding the ASP included the following: 11% (22 of 194) felt a loss of autonomy; 6% (12 of 194) felt that it interfered with clinical decision-making; and 5% (9 of 194) felt threatened. Clinicians thought that to further decrease inappropriate antibiotic use, guidelines of empiric antibiotic choices (80%, 152 of 189) should be developed, and better training in medical school and residency should be provided (80%, 152 of 189). Finally, our clinicians felt that the problem of antibiotic resistance and inappropriate antibiotic use was worse nationally than at our institution. CONCLUSIONS: A prospective-audit-with-feedback ASP was successfully developed and implemented at a children's hospital. The ASP was perceived by clinicians to reduce inappropriate antibiotic use and to improve the quality of care of hospitalized children, with minimal loss of physician autonomy or interference in clinical decision-making.

7.
Clin Infect Dis ; 49(3): 358-64, 2009 Aug 01.
Article in English | MEDLINE | ID: mdl-19548834

ABSTRACT

BACKGROUND: Escherichia coli O157:H7 (O157) is the Shiga toxin-producing E. coli (STEC) serotype most frequently isolated and most often associated with hemolytic uremic syndrome (HUS) in the United States. Non-O157 STEC serotypes can also cause serious illness, but their impact as pathogens remains undefined. We compared characteristics of non-O157 and O157 STEC infections identified through sentinel surveillance. METHODS: Sentinel sites included a metropolitan health maintenance organization laboratory and a hospital laboratory serving a small city and rural area. We received sorbitol-MacConkey agar plates from every stool culture performed at both sites during 2000-2006. Colony sweeps were screened for stx1 and stx2 by polymerase chain reaction. E. coli identity, serotype, and presence of stx1 and/or stx2 were confirmed on individual isolates. RESULTS: Two hundred six STEC isolates were identified: 108 (52%) were non-O157 serotypes, and 98 (48%) were O157. Of non-O157 cases, 54% involved bloody diarrhea, and 8% involved hospitalization. Non-O157 isolates with at least stx2 were not more likely to cause severe illness (bloody diarrhea, hospitalization, or HUS) than were non-O157 isolates with only stx1. O157 cases were more likely than non-O157 cases to involve bloody diarrhea (78% vs 54%; P < .001), hospitalization (34% vs 8%; P < .001 and HUS (7% vs 0%; P = .005). When including only isolates with at least stx2, O157 cases were still more likely to involve bloody diarrhea (78% vs 56%; P = .02) and hospitalization (33% vs 12%; P = .01) than non-O157 cases. CONCLUSIONS: Differences in severity among STEC infections could not be explained by stx2, suggesting that additional factors are important in STEC virulence.


Subject(s)
Escherichia coli Infections/microbiology , Escherichia coli Infections/pathology , Shiga-Toxigenic Escherichia coli/isolation & purification , Shiga-Toxigenic Escherichia coli/pathogenicity , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Child , Child, Preschool , Escherichia coli Infections/epidemiology , Escherichia coli O157/isolation & purification , Escherichia coli O157/pathogenicity , Escherichia coli Proteins/genetics , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Minnesota/epidemiology , Serotyping , Shiga Toxin 1/genetics , Shiga Toxin 2/genetics , Shiga-Toxigenic Escherichia coli/classification , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...